Obinutuzumab vs rituximab for relapsing childhood kidney syndrome
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is age 3 to 18 years
- Your child has steroid-dependent or frequent-relapsing nephrotic syndrome, with specific timing and number of relapses
- Your child is in remission right before randomization (three urine dipstick tests without protein)
- Your child has had no rituximab in the last 6 months, and no obinutuzumab ever
- Your child’s blood counts and kidney function meet limits (including minimum white blood cells/platelets and kidney filtration)
- Vaccines are up to date, and no live vaccine within the last 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This trial tests if the drug obinutuzumab can help people with a blood vessel inflammation called cryoglobulinemia vasculitis when rituximab no longer works or causes side effects. It is a single-arm study, meaning everyone gets the new drug.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This study tests a new drug called obinutuzumab to see if it can keep nephrotic syndrome from coming back in adults who need repeated rituximab treatments. The goal is to see if obinutuzumab works better at controlling the disease compared to current care.
Hear when a new Steroid-Sensitive Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.